This review provided systematic evidence for evaluating the efficacy and safety of particle therapy for inoperable locally advanced NSCLC. Based on 19 studies with a total sample size of 851 patients, the pooled data reported that the OS, PFS, and LC rates at 2 years were 61.3%, 37.9% and 82.2%. The pooled 5-year OS, PFS, and LC rates were 41.3%, 25.3% and 61.5%. The incidence rates of grade 3/4 esophagitis, dermatitis, and pneumonia were 2.6%, 2.6% and 3.4%.